Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Endometrial Adenocarcinoma: early-phase trial registry
3 of 14 indexed Endometrial Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 3 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Endometrial Adenocarcinoma: 14 US clinical trials tracked, 3 recruiting.
Endometrial Adenocarcinoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition endometrial-adenocarcinoma
OPEN 3 | RECR 21% | LATE 0 | EARLY 13 | RANK #1230 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Cervical Adenocarcinoma (21% recruiting · 14 trials)
Endometrial Adenocarcinoma lists 3 open slots (21% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Endometrial Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Endometrial Adenocarcinoma is recruiting below its size-band peers.
3 of 14 indexed trials (21.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Endometrial Adenocarcinoma research.
National Cancer Institute (NCI) accounts for 6 of 14 trials (42.9%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Endometrial Adenocarcinoma enrolment sits around 81 participants.
Median target enrolment is 81 among the 14 trials that report a genuine target (sentinel values excluded). 8 of those (57.1%) plan for fewer than 100 participants.
-
Endometrial Adenocarcinoma research is mostly interventional.
13 interventional and 1 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Acrivon Therapeutics
NCT05548296
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics
NCT06399757
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
National Cancer Institute (NCI)
NCT05112601
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
NCT00977574
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
NCT03660826
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
NCT02208375
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
NCT03586661
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
NCT04106414
Prognostic Biomarkers in Patients With Endometrial Cancer
Gynecologic Oncology Group
NCT01208467
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Gynecologic Oncology Group
NCT00064025
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
National Cancer Institute (NCI)
NCT01307631
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Gynecologic Oncology Group
NCT01225887
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
NCT00006089
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
NCT01935973
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Endometrial Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Endometrial Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Endometrial Adenocarcinoma page
14 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Endometrial Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Endometrial Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Adenocarcinoma condition card totals 14 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.